エルロチニブ
エルロチニブ 物理性質
- 融点 :
- 159-160 °C
- 沸点 :
- 553.6±50.0 °C(Predicted)
- 比重(密度) :
- 1.24
- 貯蔵温度 :
- Keep in dark place,Sealed in dry,Store in freezer, under -20°C
- 溶解性:
- クロロホルム(微量)、DMSO(微量)、メタノール(微量)
- 外見 :
- 個体
- 酸解離定数(Pka):
- 5.32±0.30(Predicted)
- 色:
- 白い
- CAS データベース:
- 183321-74-6(CAS DataBase Reference)
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
Sigma-Aldrich Japan
|
SML3621 |
≥98% (HPLC)
Erlotinib ≥98% (HPLC) |
183321-74-6 |
50MG |
¥11300 |
2023-06-01 |
購入 |
Sigma-Aldrich Japan
|
SML3621 |
≥98% (HPLC)
Erlotinib ≥98% (HPLC) |
183321-74-6 |
250MG |
¥42600 |
2023-06-01 |
購入 |
エルロチニブ 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬
説明
Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-
associated kinase activity (IC
50 = 2.5 μM). This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED
50 value of 9 mg/kg. Erlotinib also suppresses cyclin-
dependent kinase 2 (Cdk2) activity in breast cancer cells (IC
50 = 4.6 μM) and JAK2 mutant JAK2
V617F positive hematopoietic progenitor cells (IC
50 = 5 μM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.
使用
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.
定義
ChEBI: A quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.
一般的な説明
Class: receptor tyrosine kinase
Treatment: NSCLC
Oral bioavailability = 60%
Elimination half-life = 36 h
Protein binding = 93%
副作用
- Burning, tingling, numbness or pain in the hands, arms, feet, or legs.
- cough or hoarseness.
- diarrhea (severe)
- difficult or labored breathing.
- fever or chills.
- rash (severe)
- sensation of pins and needles.
- stabbing chest pain.
エルロチニブ 上流と下流の製品情報
原材料
準備製品
エルロチニブ 生産企業
Global( 436)Suppliers
183321-74-6(エルロチニブ)キーワード:
- 183321-74-6
- ERLOTINIB
- ERLOTINIB HCL SALT
- 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
- n-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine
- Erlotinib Hydrochloirde
- 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-
- ERLOTININ
- N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
- Erlotinib & its intermediates
- CP-358774, Ro 50-8231
- Erlotinib Free Base
- OSI 744
- R 1415
- Erlotinib &aMp
- its interMediates
- O-desmethyl erlotinib carboxylic acid
- Erlotinib N-(3-Ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine
- Erlotinib ERLOTINIB
- Erlotinib (OSI-744)
- Erlonat
- Erlotinib (Tarceva)
- NSC-71878
- OSI744;CP-358774;NSC-71878;ERLOTINIB HCL (OSI 744;CP358774;NSC718781)
- Erlotinib USP/EP/BP
- Erlotinib (OSI744, Tarceva)
- ErlotinibQ: What is
Erlotinib Q: What is the CAS Number of
Erlotinib Q: What is the storage condition of
Erlotinib Q: What are the applications of
Erlotinib
- ERLOTINIB HCL
- Tarceva
- Erlortinib
- Erlotinib 183321-74-6
- エルロチニブ
- 4-[(3-エチニルフェニル)アミノ]-6,7-ビス(2-メトキシエトキシ)キナゾリン
- N-(3-エチニルフェニル)-6,7-ビス(2-メトキシエトキシ)キナゾリン-4-アミン
- 4-(3-エチニルフェニルアミノ)-6,7-ビス(2-メトキシエトキシ)キナゾリン
- 4-(3-エチニルフェニルアミノ)-6,7-ビス(3-オキサブタン-1-イルオキシ)キナゾリン
- N-(3-エチニルフェニル)-6,7-ビス(2-メトキシエトキシ)-4-キナゾリンアミン